The efficacy of amiodarone used in combination with a pacemaker cardioverter defibrillator (PCD) to decrease episodes of ventricular tachycardia and subsequent PCD shocks is not clear. We examined a retrospective registry of 82 patients with PCD implantation to define the efficacy of amiodarone treatment. We compared patients treated with amiodarone (for 24 consecutive months without interruption) versus no amiodarone. In patients treated with amiodarone there was a 3-fold increase (p = 0.02) in PCD shocks; in patients not on beta-blockers, amiodarone resulted in a 6-fold increase (p < 0.05) in PCD shocks. Patients with a left ventricular ejection fraction >30% on amiodarone and patients <72 years old had increases (p < 0.05) in PCD shocks. In conclusion, patients treated with amiodarone had more PCD shocks than those not treated. These findings are unexpected and merit a prospective study.

Keywords:
Amiodarone, Pacemaker (internal) cardioverter defibrillator
1.
Myerburg RJIAJ, Mitrani RM, Kessler KM, Castellanos A: Frequency of sudden cardiac death and profiles of risk. Am J Cardiol 1997;80:10F–19F.
2.
Qi X, Dorian P. Antiarrhythmic drugs and ventricular defibrillation energy requirements. Chin Med J 1999;112:1147–1152.
3.
Schlapfer J, Rapp F, Kappenberger L, Fromer M: Electrophysiologically guided amiodarone therapy versus the implantable cardioverter-defibrillator for sustained ventricular tachyarrhythmias after myocardial infarction: Results of long-term follow-up. J Am Coll Cardiol 2002;39:1813–1819.
4.
Anonymous: Are implantable cardioverter-defibrillators or drugs more effective in prolonging life? The Antiarrhythmics Versus Implantable Defibrillators (AVID) Trial Executive Committee. Am J Cardiol 1997;79:661–663.
5.
Connolly SJ, Gent M, Roberts RS, et al: Canadian implantable defibrillator study (CIDS): A randomized trial of the implantable cardioverter defibrillator against amiodarone. Circulation 2000;101:1297–1302.
6.
Seidl K, Senges J: Geographic differences in implantable cardioverter defibrillator usage. J Cardiovasc Electrophysiol 2002;13:S100–S105.
7.
Moss AJ, Zareba W, Hall WJ, et al: Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med 2002;346:877–883.
8.
Hurst T, Hinriccs M, Breidenbach C, Katz N, Waldecker B: Detection of myocardial injury during transvenous implantation of automatic cardioverter-defibrillators. J Am Coll Cardiol 1999;34:402–408.
9.
Movsowitz C, Marchlinski FE: Interactions between implantable cardioverter-defibrillators and class III agents. Am J Cardiol 1998;82:41I-48I.
10.
Manz M, Jung W, Luderitz B: Interactions between drugs and devices: Experimental and clinical studies. Am Heart Jo 1994;127:978–984.
11.
Dolack GL: Clinical predictors of implantable cardioverter-defibrillator shocks: Results of the CASCADE trial. Cardiac Arrest in Seattle, Conventional versus Amiodarone Drug Evaluation. Am J Cardiol 1994;73:237–241.
12.
Anderson JL: Contemporary clinical trials in ventricular tachycardia and fibrillation: Implications of ESVEM, CASCADE, and CASH for clinical management. J Cardiovasc Electrophysiol 1995;6:880–886.
13.
Marchlinski FE, Zado ES, Deely MP, Saligan J, Ashar M, Nayak H: Concomitant device and drug therapy: Current trends, potential benefits, and adverse interactions. Am J Cardiol 1999;84:69R–75R.
14.
Cairns JA, Connolly SJ, Roberts R, Gent M: Randomised trial of outcome after myocardial infarction in patients with frequent or repetitive ventricular premature depolarisations: CAMIAT. Canadian Amiodarone Myocardial Infarction Arrhythmia Trial Investigators. Lancet 1997;349:675–682.
15.
Boutitie F, Boissel JP, Connolly SJ, et al: Amiodarone interaction with beta-blockers: Analysis of the merged EMIAT (European Myocardial Infarct Amiodarone Trial) and CAMIAT (Canadian Amiodarone Myocardial Infarction Trial) databases. Circulation 1999;99:2268–2275.
16.
Pacifico A, Hohnloser SH, Williams JH, et al: Prevention of implantable-defibrillator shocks by treatment with sotalol. d,l-Sotalol Implantable Cardioverter-Defibrillator Study Group. N Engl J Med 1999;340:1855–1862.
17.
Irvine J, Dorian P, Baker B, et al: Quality of life in the Canadian Implantable Defibrillator Study (CIDS). Am Heart J 2002;144:282–289.
18.
McCollam PL, Nappi JM: Concomitant amiodarone and the implantable cardioverter-defibrillator: Is there a place? Ann Pharmacother 1993;27:736–741.
19.
Elliott PM: The role of pharmacologic treatment to prevent sudden death in the implantable cardioverter defibrillator era. Curr Cardiol Rep 2001;3:167–172.
20.
Dorian P: Combination ICD and drug treatments-best options. Resuscitation. 2000;45:S3–S6.
21.
Huang SK, Tan de Guzman WL, Chenarides JG, Okike NO, Vander Salm TJ: Effects of long-term amiodarone therapy on the defibrillation threshold and the rate of shocks of the implantable cardioverter-defibrillator. Am Heart J 1991;122:720–727.
22.
Antiarrhythmics versus Implantable Defibrillators (AVID) – rationale, design, and methods. Am J Cardiol 1995;75:470–475.
23.
Futterman LG, Lemberg L: Sudden cardiac death – preventable – reversible. Am J Crit Care 1997;6:472–482.
24.
Connolly SJ, Gent M, Roberts RS, et al: Canadian Implantable Defibrillator Study (CIDS): Study design and organization. Am J Cardiol 1993;72:103F–108F.
25.
Connolly SJ, Hallstrom AP, Cappato R, et al: Meta-analysis of the implantable cardioverter defibrillator secondary prevention trials. AVID, CASH and CIDS studies. Antiarrhythmics vs. Implantable Defibrillator study. Cardiac Arrest Study Hamburg. Canadian Implantable Defibrillator Study. Eur Heart J 2000;21:2071–2078.
26.
Khalighi K, Daly B, Leino EV, et al: Clinical predictors of transvenous defibrillation energy requirements. Am J Cardiol 1997;79:150–153.
27.
Dorian P, Newman D, Harris L, Downar E: Sotalol in patients with implanted automatic defibrillators: Effects on defibrillation and comparison with amiodarone. Can J Cardiol 1994;10:193–200.
28.
Jung W, Manz M, Pfeiffer D, Tebbenjohanns J, Pizzulli L, Luderitz B: Effects of antiarrhythmic drugs on epicardial defibrillation energy requirements and the rate of defibrillator shocks. Pacing Clin Electrophysiol 1993;16:198–201.
29.
Hilleman DE, Bauman AL: Role of antiarrhythmic therapy in patients at risk for sudden cardiac death: An evidence-based review. Pharmacotherapy. 2001;21:556–575.
30.
Pelosi F, Jr., Oral H, Kim MH, et al: Effect of chronic amiodarone therapy on defibrillation energy requirements in humans. J Cardiovasc Electrophysiol 2000;11:736–740.
31.
Daoud EG, Man KC, Horwood L, Morady F, Strickberger SA: Relation between amiodarone and desethylamiodarone plasma concentrations and ventricular defibrillation energy requirements. Am J Cardiol 1997;79:97–100.
32.
Zhou L, Chen BP, Kluger J, Fan C, Chow MS: Effects of amiodarone and its active metabolite desethylamiodarone on the ventricular defibrillation threshold. J Am Coll Cardiol 1998;31:1672–1678.
33.
Exner DV, Reiffel JA, Epstein AE, et al: Beta-blocker use and survival in patients with ventricular fibrillation or symptomatic ventricular tachycardia: The Antiarrhythmics Versus Implantable Defibrillators (AVID) trial. J Am Coll Cardiol 1999;34:325–333.
34.
Melichercik J, Goepfrich M, Breidenbach T, Von Hodenberg E: Rise of defibrillation energy requirement under carvedilol therapy. Pacing Clin Electrophysiol 2001;24:1417–1419.
35.
Nolan PE, Jr: Pharmacokinetics and pharmacodynamics of intravenous agents for ventricular arrhythmias. Pharmacotherapy 1997;17:65S–75S; discussion 89S–91S.
36.
Alboni P: The amiodarone-beta blockers combination could represent an alternative treatment in patients at risk for sudden death in which a benefit from implantable defibrillators has not been clearly demonstrated. Ital Heart J 2002;3:337–343.
37.
Aronow WS: The management of ventricular arrhythmias in older patients after CAST. Drugs Aging 1995;6:112–124.
38.
Quan KJ, Lee JH, Costantini O, et al: Favorable results of implantable cardioverter-defibrillator implantation in patients older than 70 years. Ann Thorac Surg 1997;64:1713–1717.
39.
Panotopoulos PT, Axtell K, Anderson AJ, et al: Efficacy of the implantable cardioverter-defibrillator in the elderly. J Am Coll Cardiol 1997;29:556–560.
40.
Trappe HJ, Pfitzner P, Achtelik M, Fieguth HG: Age-dependent efficacy of implantable cardioverter-defibrillator treatment: Observations in 450 patients over an 11-year period. Heart 1997;78:364–370.
© 2003 S. Karger AG, Basel
2003
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.